Log in

NYSE:CRYCryolife Stock Price, Forecast & News

-0.29 (-1.26 %)
(As of 05/29/2020 04:00 PM ET)
Today's Range
Now: $22.73
50-Day Range
MA: $21.42
52-Week Range
Now: $22.73
Volume232,574 shs
Average Volume186,983 shs
Market Capitalization$857.83 million
P/E RatioN/A
Dividend YieldN/A
CryoLife, Inc., together with its subsidiaries, manufactures, processes, and distributes medical devices and implantable human tissues for use in cardiac and vascular surgeries worldwide. The company operates in two segments, Medical Devices and Preservation Services. It offers BioGlue, an agent for cross-linking proteins for cardiac, vascular, pulmonary, and general surgical applications; On-X mechanical heart valves for aortic and mitral indications; cardiac preservation services; PhotoFix, a bovine pericardial patch for use in cardiac and vascular repairing activities; and PerClot, an absorbable powdered hemostat for use in surgical procedures, including cardiac, vascular, orthopedic, neurological, gynecological, ENT, and trauma surgeries. The company also provides cardiac laser therapy products, which include laser consoles, related service and maintenance, and single-use, as well as fiber-optic hand-pieces for the treatment of coronary artery disease in patients with severe angina. In addition, it distributes E-vita OPEN PLUS, a hybrid stent graft system for the surgical and endovascular treatment; E-xtra DESIGN ENGINEERING products for the treatment of aortic vascular diseases; E-ventus BX, a balloon-expandable peripheral stent graft for the endovascular treatment of renal and pelvic arteries; E-liac, a stent graft used to treat aneurysmal iliac arteries, as well as aneurysmal iliac side branches; E-vita THORACIC 3G, a stent graft system for the endovascular treatment of thoracic aortic aneurysms; and E-tegra, an abdominal aortic aneurysms stent graft system for the endovascular treatment. Further, the company offers vascular preservation services; and synthetic vascular grafts for use in open aortic and peripheral vascular surgical procedures. The company serves physicians, hospitals, and other healthcare industries, as well as cardiac, vascular, thoracic, and general surgeons. CryoLife, Inc. was founded in 1984 and is headquartered in Kennesaw, Georgia.
Read More
Cryolife logo

Beat the Market (BTM) Rank

Analyst Opinion: 2.4Community Rank: 2.8Dividend Strength: 0.0Insider Behavior: 1.0Valuation: 0.6 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.37 out of 5 stars

Industry, Sector and Symbol

Industry Surgical & medical instruments
Sub-IndustryHealth Care Equipment



Sales & Book Value

Annual Sales$276.22 million
Cash Flow$0.80 per share
Book Value$7.33 per share


Net Income$1.72 million


Market Cap$857.83 million
Next Earnings Date8/4/2020 (Estimated)

Receive CRY News and Ratings via Email

Sign-up to receive the latest news and ratings for CRY and its competitors with MarketBeat's FREE daily newsletter.

Cryolife (NYSE:CRY) Frequently Asked Questions

How has Cryolife's stock been impacted by COVID-19 (Coronavirus)?

Cryolife's stock was trading at $23.87 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization. Since then, CRY stock has decreased by 4.8% and is now trading at $22.73. View which stocks have been most impacted by Coronavirus.

Do Wall Street analysts recommend investors buy shares of Cryolife?

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Cryolife in the last year. There are currently 1 hold rating and 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Cryolife.

When is Cryolife's next earnings date?

Cryolife is scheduled to release its next quarterly earnings announcement on Tuesday, August 4th 2020. View our earnings forecast for Cryolife.

How were Cryolife's earnings last quarter?

Cryolife Inc (NYSE:CRY) posted its earnings results on Thursday, April, 30th. The medical equipment provider reported ($0.08) earnings per share for the quarter, missing the Thomson Reuters' consensus estimate of $0.02 by $0.10. The medical equipment provider earned $66.43 million during the quarter, compared to analysts' expectations of $66.11 million. Cryolife had a negative net margin of 1.69% and a positive return on equity of 2.55%. The firm's revenue for the quarter was down 1.6% on a year-over-year basis. During the same period in the prior year, the company posted $0.04 EPS. View Cryolife's earnings history.

What guidance has Cryolife issued on next quarter's earnings?

Cryolife issued an update on its first quarter 2020 After-Hours earnings guidance on Wednesday, April, 1st. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $65.5-65.5 million, compared to the consensus revenue estimate of $68.38 million.

What price target have analysts set for CRY?

5 brokers have issued 12 month price objectives for Cryolife's stock. Their forecasts range from $25.00 to $29.00. On average, they anticipate Cryolife's share price to reach $27.50 in the next year. This suggests a possible upside of 21.0% from the stock's current price. View analysts' price targets for Cryolife.

Has Cryolife been receiving favorable news coverage?

Media headlines about CRY stock have trended positive recently, according to InfoTrie Sentiment Analysis. InfoTrie scores the sentiment of press coverage by monitoring more than six thousand blog and news sources. The firm ranks coverage of public companies on a scale of negative five to five, with scores nearest to five being the most favorable. Cryolife earned a media sentiment score of 2.8 on InfoTrie's scale. They also assigned media stories about the medical equipment provider a news buzz of 10.0 out of 10, indicating that recent press coverage is extremely likely to have an effect on the stock's share price in the next few days. View the latest news aboutCryolife.

Are investors shorting Cryolife?

Cryolife saw a decline in short interest during the month of April. As of April 30th, there was short interest totaling 1,240,000 shares, a decline of 15.1% from the April 15th total of 1,460,000 shares. Based on an average daily trading volume, of 311,900 shares, the short-interest ratio is currently 4.0 days. Approximately 3.4% of the company's stock are sold short. View Cryolife's Current Options Chain.

Who are some of Cryolife's key competitors?

What other stocks do shareholders of Cryolife own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Cryolife investors own include Energy Transfer LP Unit (ET), AT&T (T), Gilead Sciences (GILD), Enterprise Products Partners (EPD), Netflix (NFLX), NVIDIA (NVDA), Teva Pharmaceutical Industries (TEVA), Zoetis (ZTS), Ares Capital (ARCC) and Alibaba Group (BABA).

Who are Cryolife's key executives?

Cryolife's management team includes the following people:
  • Mr. James Patrick MacKin, Chairman, Pres & CEO (Age 52)
  • Mr. David Ashley Lee CPA, CPA, Exec. VP, COO & CFO (Age 54)
  • Ms. Jean F. Holloway, Sr. VP, Gen. Counsel, Chief Compliance Officer & Corp. Sec. (Age 62)
  • Mr. John E. Davis, Sr. VP of Global Sales & Marketing (Age 54)
  • Ms. Amy D. Horton CPA, CPA, VP & Chief Accounting Officer (Age 49)

What is Cryolife's stock symbol?

Cryolife trades on the New York Stock Exchange (NYSE) under the ticker symbol "CRY."

Who are Cryolife's major shareholders?

Cryolife's stock is owned by a variety of retail and institutional investors. Top institutional shareholders include BlackRock Inc. (15.05%), Capital Research Global Investors (7.81%), Morgan Stanley (4.00%), Morgan Stanley (4.00%), State Street Corp (3.55%) and Wasatch Advisors Inc. (2.78%). Company insiders that own Cryolife stock include Amy Horton, C Elkins Ronald, David Ashley Lee, Harvey Morgan, James P Mackin, Jean F Holloway, John E Davis, Ronald D Mccall and Scott B Capps. View institutional ownership trends for Cryolife.

Which institutional investors are selling Cryolife stock?

CRY stock was sold by a variety of institutional investors in the last quarter, including ArrowMark Colorado Holdings LLC, BlackRock Inc., Morgan Stanley, Morgan Stanley, Thrivent Financial for Lutherans, THB Asset Management, Dupont Capital Management Corp, and Citigroup Inc.. Company insiders that have sold Cryolife company stock in the last year include Jean F Holloway, Ronald D Mccall, and Scott B Capps. View insider buying and selling activity for Cryolife.

Which institutional investors are buying Cryolife stock?

CRY stock was acquired by a variety of institutional investors in the last quarter, including Capital Research Global Investors, GW&K Investment Management LLC, Loomis Sayles & Co. L P, Wasatch Advisors Inc., William Blair Investment Management LLC, Geode Capital Management LLC, Deutsche Bank AG, and State Street Corp. View insider buying and selling activity for Cryolife.

How do I buy shares of Cryolife?

Shares of CRY can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Cryolife's stock price today?

One share of CRY stock can currently be purchased for approximately $22.73.

How big of a company is Cryolife?

Cryolife has a market capitalization of $857.83 million and generates $276.22 million in revenue each year. The medical equipment provider earns $1.72 million in net income (profit) each year or $0.31 on an earnings per share basis. Cryolife employs 1,200 workers across the globe.

What is Cryolife's official website?

The official website for Cryolife is www.cryolife.com.

How can I contact Cryolife?

Cryolife's mailing address is 1655 Roberts Boulevard N.W, Kennesaw GA, 30144. The medical equipment provider can be reached via phone at 770-419-3355 or via email at [email protected]

This page was last updated on 5/31/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.